Abpro Holdings (ABP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
3 Feb, 2026Executive summary
Annual meeting scheduled to be held virtually in 2025, with voting on key proposals including director re-election, auditor ratification, and a reverse stock split.
The company recently completed a business combination, resulting in a new corporate structure and board composition.
Stockholders of record as of the set date are entitled to vote; 80,166,667 shares outstanding.
Voting matters and shareholder proposals
Proposal 1: Re-election of Ian McDonald as Class I director to serve until 2028.
Proposal 2: Ratification of Wolf & Company, P.C. as independent auditor for 2025.
Proposal 3: Approval of a 1-for-10 reverse stock split to maintain Nasdaq listing.
Board recommends voting FOR all proposals.
Board of directors and corporate governance
Board consists of five directors in three staggered classes; majority are independent per Nasdaq rules.
Committees: audit, compensation, and nominating/governance, each with independent members.
Audit committee chaired by Anthony D. Eisenberg, who is also the audit committee financial expert.
Board and committees established post-business combination in November 2024.
Code of ethics and insider trading policy in place; clawback policy adopted in 2023.
Latest events from Abpro Holdings
- Vote seeks to extend the business combination deadline, with redemption rights preserved.ABP
Proxy Filing3 Feb 2026 - Preclinical biotech with major funding needs registers large share and warrant resale, faces high dilution risk.ABP
Registration Filing3 Feb 2026 - Preclinical biotech with urgent capital needs registers up to 20.7M shares for resale under $50M SEPA.ABP
Registration Filing3 Feb 2026 - Shareholders will vote on extending the business combination deadline or face company liquidation.ABP
Proxy Filing3 Feb 2026 - Key votes include director re-election, auditor ratification, and a 1-for-10 reverse stock split.ABP
Proxy Filing3 Feb 2026 - Biotech registers major share resale and warrant exercise, faces funding and clinical risks.ABP
Registration Filing3 Feb 2026 - Biotech seeks $50M equity via SEPA amid going concern, dilution, and Nasdaq risks.ABP
Registration Filing3 Feb 2026 - Preclinical biotech seeks up to $50M via equity facility amid severe liquidity and delisting risks.ABP
Registration Filing3 Feb 2026 - Vote to approve up to $50M in stock issuance to Yorkville and potential meeting adjournment.ABP
Proxy Filing3 Feb 2026